Olga Zapletalová

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Alena Novotná, Jan Mareš, S. Ratcliffe et al. · European Journal of Neurology · 2011 · 464 citations

Medicine, Neurology, Pharmacology +17

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

Christine Collin, Edvard Ehler, G Waberzinek et al. · Neurological Research · 2010 · 278 citations

Pharmacy, Neurology, Pharmacotherapy +16

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

Ludwig Kappos, Gilles Edan, Mark S. Freedman et al. · Neurology · 2016 · 130 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +13

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9